Next-Generation Weight-Loss Drugs: The History and Future of GLP-1 Agonists
In this article
What Are GLP-1 Agonists?
GLP-1 (Glucagon-Like Peptide-1) agonists are a drug class initially developed to treat Type 2 diabetes. They mimic GLP-1, a hormone naturally produced in the body that regulates blood glucose. When their important effects on appetite reduction and weight loss were discovered, however, they revolutionized obesity treatment. This infographic offers an in-depth analysis of these transformative drugs.
A Multifaceted Mechanism of Action
Brain: Appetite Control
Stimulates satiety centers in the hypothalamus, reducing appetite and food intake.
Stomach: Slower Emptying
Slows the rate of gastric emptying, creating a longer-lasting feeling of fullness.
Pancreas: Blood Glucose Regulation
Increases insulin release and suppresses glucagon release to keep blood glucose under control.
Timeline: Development History
2005
The first GLP-1 agonist, Exenatide (Byetta), received FDA approval for Type 2 diabetes (twice-daily injections).
2010
Daily injectable Liraglutide (Victoza) was approved for diabetes.
2014
Liraglutide, under the Saxenda brand, became the first GLP-1 drug approved by the FDA for obesity treatment.
2017
Weekly injectable Semaglutide (Ozempic) entered the market for diabetes treatment.
2019
Rybelsus (Semaglutide), the first oral GLP-1 tablet, was approved for diabetes treatment.
2021
Wegovy, a higher dose of Semaglutide, received approval for obesity treatment.
2023
Dual-action (GLP-1/GIP) Tirzepatide (Zepbound, Mounjaro) set a new standard with approval for obesity.
Comparing Drug Efficacy
Clinical trials have shown significant increases in weight-loss efficacy with next-generation GLP-1 agonists. The chart below compares average percentage body-weight loss with leading FDA-approved drugs.
Mechanisms and Receptor Targets — Current and Emerging Drugs
| Drug | Class | Target Receptor(s) | Mechanism Summary | Administration | Development Status | Notes / Key Data |
|---|---|---|---|---|---|---|
| Liraglutide (Victoza / Saxenda) | Single agonist | GLP-1R ↑ | Insulin ↑, glucagon ↓, gastric emptying ↓, appetite ↓. | Daily s.c. | Approved (DM2, obesity) | Typical weight loss of 5–10%; CV risk ↓ in certain populations. |
| Semaglutide (Ozempic / Wegovy / Rybelsus) | Single agonist | GLP-1R ↑ | Insulin ↑, glucagon ↓, appetite ↓; strong weight-loss effect. | Weekly s.c. / Oral | Approved (DM2, obesity) | Average weight loss up to ~15% (obesity); benefits in CV outcomes. |
| Tirzepatide (Zepbound / Mounjaro) | Dual agonist | GLP-1R ↑ GIPR ↑ | GLP-1 + GIP synergy: insulin ↑, appetite ↓; substantial weight loss. | Weekly s.c. | Approved (DM2, obesity) | Programs achieving 20%+ weight loss; very strong glycemic control. |
| Retatrutide | Triple agonist | GLP-1R ↑ GIPR ↑ GCGR ↑ | GLP-1/GIP appetite–glycemic control; glucagon increases energy expenditure ↑ / lipolysis ↑. | Weekly s.c. | In development (trial phase) | Early studies reported a signal of weight loss approaching 24%. |
| Survodutide (BI 456906) | Dual agonist | GLP-1R ↑ GCGR ↑ | GLP-1 reduces appetite ↓; glucagon increases energy expenditure ↑; FAT/NAFLD targets. | Weekly s.c. | In development | Promising interim data in NAFLD/NASH and weight loss. |
| Pemvidutide (ALT-801) | Dual agonist (albumin-binding) | GLP-1R ↑ GCGR ↑ | Long half-life; energy expenditure ↑ through the glucagon component. | Weekly s.c. | In development | Signals of substantial reductions in weight and liver fat. |
| CagriSema (Semaglutide + Cagrilintide) | Combination | GLP-1R ↑ Amylin (analog) | GLP-1: appetite/glucose; amylin: gastric emptying and satiety ↑. | Weekly s.c. | In development | Additional weight loss compared with single agents is being reported. |
| Orforglipron | Single agonist (oral, nonpeptide) | GLP-1R ↑ | Nonpeptide oral GLP-1RA; appetite ↓, glycemic control ↑. | Daily oral | In development | Significant weight loss at high doses; an alternative to injections. |
| Danuglipron | Single agonist (oral, small molecule) | GLP-1R ↑ | Oral GLP-1RA; focused on dose/s tolerability optimization. | Daily oral | In development | Ongoing evaluations with program revisions. |
| Maridebart cafraglutide (formerly AMG-133) | Dual mode: GLP-1RA + GIPR antagonist | GLP-1R ↑ GIPR ⊝ (antagonism) | GLP-1-mediated appetite/glycemic effects + GIP signal blockade reduce fat mass ↓. | Periodic s.c. (long-acting design) | In development | Early phases have reported signals of rapid, substantial weight loss. |
Note: Mechanism summaries describe class effects; each drug’s label information, dosing and safety profile may differ. The development statuses and numerical statements here provide a general framework based on published preliminary/interim studies and may be updated over time.
Future Perspective: What Is on the Horizon?
The success of GLP-1 agonists has accelerated research into treating obesity and related metabolic diseases. The future promises more effective, safer and more patient-friendly treatments.
New Oral Formulations
Next-generation tablets with high bioavailability are being developed that could reduce the need for injections.
Triple and Quadruple Agonists
Triple agonists such as Retatrutide have shown weight loss exceeding 24% in clinical trials.
Personalized Medicine
Individualized approaches selecting the most appropriate drug according to genetic and metabolic profiles are under consideration.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.